Latest Insider Transactions at Vir Biotechnology, Inc. (VIR)
This section provides a real-time view of insider transactions for Vir Biotechnology, Inc. (VIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vir Biotechnology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vir Biotechnology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 27
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.38%
|
$0
$0.86 P/Share
|
|
Sep 22
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+6.91%
|
$8,000
$1.53 P/Share
|
|
Sep 21
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
4,125
-3.97%
|
$206,250
$50.0 P/Share
|
|
Sep 21
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,125
+3.82%
|
$4,125
$1.53 P/Share
|
|
Sep 17
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.47%
|
$789,048
$52.69 P/Share
|
|
Sep 15
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.3%
|
$245,000
$49.97 P/Share
|
|
Sep 07
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
4,125
-2.0%
|
$202,125
$49.5 P/Share
|
|
Sep 07
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,125
+3.82%
|
$4,125
$1.53 P/Share
|
|
Sep 01
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.48%
|
$245,000
$49.52 P/Share
|
|
Sep 01
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$5,000
$1.53 P/Share
|
|
Aug 30
2021
|
Janet Napolitano Director |
SELL
Open market or private sale
|
Direct |
1,435
-29.84%
|
$73,185
$51.15 P/Share
|
|
Aug 30
2021
|
Janet Napolitano Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+22.98%
|
$58,835
$41.64 P/Share
|
|
Aug 25
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,750
-2.68%
|
$137,500
$50.0 P/Share
|
|
Aug 25
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+2.61%
|
$2,750
$1.53 P/Share
|
|
Aug 24
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$66,000
$48.0 P/Share
|
|
Aug 24
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Aug 23
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
13,750
-12.12%
|
$687,500
$50.0 P/Share
|
|
Aug 23
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,750
+10.81%
|
$13,750
$1.53 P/Share
|
|
Aug 23
2021
|
Steven J. Rice Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
10,000
-33.33%
|
$500,000
$50.0 P/Share
|
|
Aug 23
2021
|
Steven J. Rice Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+25.0%
|
$120,000
$12.76 P/Share
|
|
Aug 19
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.47%
|
$667,656
$44.94 P/Share
|
|
Aug 18
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.38%
|
$210,000
$42.23 P/Share
|
|
Aug 18
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$5,000
$1.53 P/Share
|
|
Aug 10
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$56,375
$41.0 P/Share
|
|
Aug 10
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Aug 04
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.38%
|
$170,000
$34.92 P/Share
|
|
Aug 04
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$25,000
$5.17 P/Share
|
|
Jul 29
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-12.83%
|
$431,790
$37.11 P/Share
|
|
Jul 27
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$49,500
$36.72 P/Share
|
|
Jul 27
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Jul 21
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,630
-4.06%
|
$171,310
$37.44 P/Share
|
|
Jul 21
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,630
+3.91%
|
$4,630
$1.57 P/Share
|
|
Jul 19
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.46%
|
$561,438
$37.29 P/Share
|
|
Jul 15
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-20.23%
|
$408,450
$35.56 P/Share
|
|
Jul 13
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$49,500
$36.72 P/Share
|
|
Jul 13
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Jul 07
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.21%
|
$200,000
$40.54 P/Share
|
|
Jul 07
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$25,000
$5.17 P/Share
|
|
Jul 01
2021
|
Robert J More Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,671
+3.38%
|
$71,853
$43.53 P/Share
|
|
Jul 01
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
33,412
+36.37%
|
-
|
|
Jul 01
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,000,000
-15.58%
|
-
|
|
Jul 01
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
47,897
+36.36%
|
-
|
|
Jul 01
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
4,000,000
-15.58%
|
-
|
|
Jul 01
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-5.9%
|
$525,150
$45.25 P/Share
|
|
Jun 29
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$63,250
$46.63 P/Share
|
|
Jun 29
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Jun 25
2021
|
Steven J. Rice Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
3
-0.02%
|
$150
$50.0 P/Share
|
|
Jun 25
2021
|
Steven J. Rice Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3
+0.02%
|
$36
$12.76 P/Share
|
|
Jun 23
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.43%
|
$8,000
$1.53 P/Share
|
|
Jun 22
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
8,348
+24.98%
|
-
|